No abstract

A novel sensitive and cost-effective spectrofluorimetric method has been developed and validated for determination of lisinopril (an angiotensin converting enzyme inhibitor) in its pure form and pharmaceutical preparations. The method is based on the reaction of the drug with ninhydrin and phenylacetaldehyde in buffered medium (pH 7.0) to form a highly fluorescent product measured at 460 nm after excitation at 390 nm. Different experimental parameters were optimized and calibration curve was constructed. The fluorescence-concentration relationship was linear in the range of 0.15-4.0 μg mL . The calculated Limit of detection (LOD) and Limit of quantitation (LOQ) were 0.04 and 0.12 μg mL , respectively. The method was successfully applied for the analysis of pharmaceutical preparations containing the studied drug either alone or co-formulated with hydrochlorothiazide. The obtained results were in agreement with those of the reported method in respect to accuracy and precession. Moreover, the method was applied content uniformity testing according to United States Pharmacopeia (USP) guidelines.

Lisinopril, an ACE inhibitor, was selectively determined in pharmaceutical products through switch on the fluorescence of fluorescamine.

Two new, simple, fast and sensitive spectrophotometric methods were developed for analysis of binary mixtures of Lisinopril (LIS) and hydrochlorothiazide (HCT). These methods were absorptivity factor method and ratio subtraction method. In the first method, calculations were made using the absorbance of the mixtures at 211 nm where LIS absorptivity is half HCT absorptivity. On the other hand, the second method was based on obtaining the original spectrum of LIS from the zero order spectrum of the binary mixture then determining the concentration of LIS from its linear regression equation. HCT concentration in both methods was determined from the absorbance at 270 nm where a lack of interference of LIS occurs. The methods were validated according to ICH and applied successfully on different ratios of laboratory mixtures and on pharmaceutical tablets with excellent accuracy and precision.

Introduction:Dermoscopy is a non-invasive method that allows evaluation of colors and microstructures of the epidermis, the dermoepidermal junction, and the papillary dermis not visible to the naked eye. Aim of the work: The present study aims to evaluate the role of dermoscopy in diagnosis of superficial cutaneous fungal infections. Patients and methods: The present study had included 120 patients suspected clinically to have superficial cutanous fungal infections from the attendants of Dermatology Outpatient Clinic, Minia University Hospital and chosen randomly over a period of 12 months (From the beginning of December 2015 to the end of November 2016). Results:The present study was conducted on 120 patients over a period of 12 months (From the beginning of December 2015 to the end of November 2016) from the attendants of Dermatology Outpatient Clinic, Minia University Hospital. Discussion: Superficial fungal infections of the skin, scalp and nails are very common and have been reported worldwide. The most common causative agents of these mycoses are dermatophytes, yeasts and molds. Summary: Dermoscopy should be regarded as a safe and rapid diagnostic tool that assists in clinical examination and management decision in dermatology, as the stethoscope does for diagnosing heart, lung or abdominal problems. As a consequence, dermoscopy can be nowadays seen as the dermatologists' stethoscope